Avandia (rosiglitazone maleate) is an oral anti-diabetic agent manufactured by GlaxoSmithKline that helps lower blood sugar levels to manage type 2 diabetes (or non-insulin dependent diabetes) by increasing insulin sensitivity. The Federal Drug Administration approved Avandia on May 25, 1999. It's estimated that 1 million Americans took Avandia in 2006.
The FDA's Center for Drug Evaluation and Research (CDER) ensures that drugs are safe and effective. While the CDER does not test drugs, it does conduct limited research in the areas of drug quality, safety, and effectiveness. On May 21, 2007, the FDA issued a safety alert after safety data from controlled clinical trials indicated that there was a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia.
The most serious risk associated with taking Avandia is heart failure. Avandia can cause your body to keep extra fluid (fluid retention), which leads to swelling and weight gain. Extra body fluid can make some heart problems worse or lead to heart failure.
Other side effects associated with taking Avandia include:
If you have taken Avandia and suffered an Avandia-related injury or if you are a close family member of someone who died as a result of an Avandia-related injury, you may be able to file an-Avandia lawsuit.
If you have been taking Avandia, first see your doctor as your health is your number one priority. If you have an Avandia-related claim, contact an attorney experienced in Avandia litigation. Claims can be made through class action suits if there are many people with the same types of claims involving Avandia-related injuries or deaths. The class action rule is intended to improve court efficiency by allowing a large group of people with similar claims to join together in one lawsuit.
If you're aware of a serious adverse reaction to Avandia, the FDA encourages you to make a MedWatch report or call 1-800-FDA 1088.
a lien that requires no further action to be made enforceable and that identifies the lienor, the property subject to the lien, and the amount of the lien
More Legal News